Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Remedy for diabetes

A technology for diabetes and therapeutic agents, applied in the field of feed and feed additives, which can solve the problems of no reports of improving insulin resistance, no indication of effectiveness of hydroxyproline and hydroxyproline derivatives, etc.

Inactive Publication Date: 2006-05-24
KYOWA HAKKO KOGYO CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Hydroxyproline is known to have the effect of inhibiting skin aging and improving skin texture (International Publication No. 00 / 51561 pamphlet, Japanese Patent Application Publication No. 2002-80321), anti-inflammatory effect, anti-rheumatic effect, analgesic effect and wound healing effect (Japanese Unexamined Patent Publication No. 8-337526) and other pharmacological effects, but there is no report on the therapeutic effect on diabetes and the effect on improving insulin resistance
[0005] In addition, although monohydroxylated amino acids are known to have insulin-like and / or insulin-sensitivity-promoting effects (Japanese Patent Application Publication No. 2003-508435), no effective combination with hydroxyproline and hydroxyproline derivatives has been shown. sexual data

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Remedy for diabetes
  • Remedy for diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Fifteen type II diabetes animal model KK-Ay / Ta Jcl mice (CREA, Japan, male, 6 weeks old) were divided into 3 groups with 5 mice in each group, which were designated as the first group to the third group.

[0082] The mice in groups 1 to 3 were allowed to eat and drink freely. The mice in the first group were given a commercially available feed CE-2 (manufactured by CREA Japan). The mice of the second group ingested CE-2 supplemented with 1% by weight of trans-4-hydroxy-L-proline (manufactured by Kyowa Hakko Kogyo Co., Ltd., hereinafter abbreviated as hydroxyproline). The mice in the third group ingested CE-2 supplemented with 1% by weight of trans-N-acetyl-4-hydroxy-L-proline (manufactured by Kyowa Hakko Kogyo Co., Ltd., hereinafter abbreviated as N-acetylhydroxyproline) .

[0083] Blood was collected from the tail vein on the first day and 17 days after the start of the experiment, and the blood glucose level without fasting was measured with MEDISAFE leaderGR-101 (m...

Embodiment 2

[0094] Fifteen type II diabetes animal model KK-Ay / Ta Jcl mice (CREA, Japan, male, 6 weeks old) were divided into 3 groups with 5 mice in each group, which were designated as the first group to the third group.

[0095] The mice in groups 1 to 3 were allowed to eat and drink freely. The mice in the first group were given a commercially available feed CE-2 (manufactured by CREA Japan). The mice of the second group ingested CE-2 supplemented with 1% by weight of trans-4-hydroxy-L-proline ethyl ester (manufactured by Sanyo Chemical Laboratories, hereinafter abbreviated as hydroxyproline ethyl ester). Let the mice in the third group ingest trans-N, O-diacetyl-4-hydroxy-L-proline oleyl ester (manufactured by Nippon Chemical Corporation, hereinafter abbreviated as diacetyl hydroxyproline oil) added with 1% by weight. Enyl esters) CE-2.

[0096] On the first day of the experiment and after the 10th day, blood was collected from the tail vein, and the blood glucose value without fas...

Embodiment 3

[0106] Sixteen type II diabetes animal model KK-Ay / Ta Jcl mice (CREA, Japan, male, 6 weeks old) were divided into 2 groups of 8 mice each, designated as Group 1 and Group 2.

[0107] After an 18-hour fast, physiological saline was orally administered to the mice of Group 1, and 20% (w / v) Aqueous solution of N-acetylhydroxyproline (dissolved in physiological saline). One hour later, 40% (w / v) glucose aqueous solution was orally administered to the mice of the first group and the second group at 2 g / kg body weight B.W. to load them with glucose. Blood was collected from the tail vein 60 minutes before (-60 minutes), at the time of administration (0 minutes), 30 minutes after administration, and 120 minutes after administration of the glucose solution, and blood glucose levels were measured using MEDISAFE leader GR-101. Values ​​are represented by mean±standard error (n=8), and statistical reliability (p value) is calculated by t test.

[0108] The measurement results of the b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The object of the present invention is to provide a therapeutic agent for diabetes, an agent for improving insulin resistance, or a food and beverage, a food and beverage additive, feed or a feed additive for treating diabetes or improving insulin resistance. In order to solve this problem, the present invention provides a therapeutic agent for diabetes containing hydroxyproline, a hydroxyproline derivative, or a pharmacologically acceptable salt thereof as an active ingredient, and an insulin resistance improving agent for use in the treatment of diabetes or Food and drink, food and drink additives, feed and feed additives for insulin resistance improvement.

Description

technical field [0001] The present invention relates to a therapeutic agent for diabetes, an agent for improving insulin resistance, food and drink for treating diabetes or improving insulin resistance, food and drink additives, feed and feed additives. Background technique [0002] So far, there are known therapeutic agents for diabetes that promote insulin secretion such as sulfonylureas and sulfonamides, therapeutic agents for diabetes that improve insulin resistance such as thiazolidine or biguanides, and α-glucosidase inhibitors. A therapeutic agent for diabetes that improves postprandial blood sugar, etc. These therapeutic agents are used alone or in combination in the treatment of diabetes. [0003] Hydroxyproline, as the main constituent amino acid in collagen, widely exists in nature. In addition to its N-acetyl compound being used as an anti-inflammatory drug, it is also used as a carbapenem antibiotic substance or a blood pressure lowering drug, an anti-asthma d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D207/16A23K1/16A23L1/30A23L1/305A23L2/52A61K31/401A61P3/10
CPCA23L2/52A23V2002/00A61K31/401A23K20/142A23L33/175A61P3/00A61P3/10A61P3/08A61P43/00A61P5/50A23V2250/064A61K31/40C07D207/16
Inventor 神谷俊一白井章雄高田美穗荻野史子
Owner KYOWA HAKKO KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com